News & Events – Sumitovant

Select Company

March 02, 2021Sumitovant Biopharma’s Portfolio of Innovative Companies Achieve Significant Clinical and Corporate Milestones in its Third Quarter of Operation
January 26, 2021Sumitovant Biopharma Announces Myovant Sciences Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
January 04, 2021Sumitovant Biopharma Announces the Appointment of Industry Veteran, David Marek, as Chief Executive Officer of Myovant Sciences
December 28, 2020Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
December 23, 2020Sumitovant Biopharma Announces Urovant Sciences Receives U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
December 18, 2020Sumitovant Biopharma Announces Myovant Sciences receives FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
November 12, 2020Sumitovant Biopharma and Urovant Sciences Announce Sumitovant’s Acquisition of Remaining Stake in Urovant
June 22, 2020Sumitovant Biopharma Announces Priority Review and FDA Acceptance of Myovant Sciences New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer
June 19, 2020Sumitovant Biopharma Announces Urovant Sciences Collaboration with Sunovion Pharmaceuticals
June 02, 2020Sumitovant Biopharma Announces Myovant Sciences’ Submission of New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
1 2 Next »